HomeCell Signalingα1-Adrenoceptor Characteristics and Modulators

α1-Adrenoceptor Characteristics and Modulators

Alpha 1 Adrenoceptor Activation

α1-Adrenoceptors are widely distributed, and are activated either by norepinephrine released from sympathetic nerve terminals or by epinephrine released from the adrenal medulla. Receptor activation mediates a variety of functions, including contraction of smooth muscle, cardiac stimulation, cellular proliferation/apoptosis and activation of hepatic gluconeogenesis and glycogenolysis. α1-Adrenoceptors are also widely distributed within the CNS, where their activation generally results in depolarization and increased neuronal firing rate. Most of the peripheral actions of α1-adrenoceptors are mediated through phosphatidylinositol turnover, while there is evidence for activation of adenylyl cyclase within the CNS.


Three distinct α1-adrenoceptor proteins have been cloned; after some confusion in nomenclature, it has now been established that these three recombinant α1-adrenoceptors, designated as α1a, α1b and α1d correspond to the pharmacologically defined α1a, α1b and α1d adrenoceptors in native tissues. Multiple slice variants of the α1a adrenoceptor have been identified; however, they appear to have identical pharmacological characteristics. The α1-adrenoceptor mediating contraction of several vascular and urogenital tissues has distinct pharmacology from the other 3 subtypes, and has been designated as the α1I adrenoceptor. This receptor has not been cloned; it now appears that the α1I adrenoceptor represents a discrete affinity state of the α1a adrenoceptor.

Selective Expression

The subcellular location of expressed recombinant α1-adrenoceptors may be subtype dependent. Chloroethylclonidine, commonly used as a selective α1b antagonist for receptor subclassification, may be able to alkylate all α1-adrenoceptors, with its apparent selectivity for α1b versus α1a adrenoceptors, at least in cells expressing recombinant receptors, due to accessibility only to the α1b receptor. Evidence shows that it may be possible to design peptides which can selectively antagonize α1-adrenoceptor subtypes.

Mediated Response

In most cases, the particular subtype involved in an α1-adrenoceptor mediated response has not yet been defined. This is due in part to the lack of subtype selective antagonists suitable for in vivo evaluation. Depending on the species and/or vascular bed, each α1-adrenoceptor subtype can contribute to vascular contraction. For example, contraction of the rat caudal artery is mediated by the α1a adreceptor, canine aorta by the α1b and rat aorta by the α1d adrenoceptor. The response to α1-adrenoceptor stimulation in many canine and human vessels has α1I pharmacology. Knockout of either α1a, α1b or α1d adrenoceptor significantly attenuates the pressor response to α1-adrenoceptor activation in the mouse. Contraction of prostatic and urethral smooth muscle appears to be mediated by the α1I adrenoceptor. α1-Adrenoceptor antagonists having selective affinity for α1a and α1I adrenoceptors, as well as antagonists having affinity for both α1a and α1d adrenoceptors, have been evaluated clinically for the treatment of benign prostatic hyperplasia. However, it appears that these drugs are not superior to the non-subtype selective α1-adrenoceptor antagonists, which have been proven to be effective for this indication.

Accepted Alpha 1 Adrenoreceptor Modulators

The table below contains accepted modulators and additional information. Compare these modulators as well as several similar products (A0232, SML0460, and Z2777) in the "All Products" section that follows.


A-61603: N-[5-(4,5-Dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide hydrobromide
BMY 7378: 8-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-8-azasprio[4.5]decane-7,9-dione
HEAT: 2-(β-4-Hydroxyphenyl)ethylaminomethyltetralone
L-762,459: (±)-1-(3-{[5-Carbamoyl-2-{2-[(4-hydroxy-3-iodobenzimidoyl)-amino]-ethoxy-methyl}-6-methyl-4-(4-nitrophenyl)-1,4-dihydropyridine-4-carboxylic acid methyl ester
L-765,314: 4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline
RS-17053: (N-[2-(2-Cyclopropylmethoxyphenoxy)ethyl]-5-chloro-α,α-dimethyl-1H-indole-3-ethanamine
SKF-89748: 1,2,3,4-Tetrahydro-8-methoxy-5-(methylthio)-2-naphthalenamine

All Products


Bylund D. 2002. Adrenoceptors. in: The IUPHAR Compendium of Receptor Characterization and Classification. 2. London, UK: IUPHAR Media.
Chen Z, Rogge G, Hague C, Alewood D, Colless B, Lewis RJ, Minneman KP. 2004. Subtype-selective Noncompetitive or Competitive Inhibition of Human ? 1 -Adrenergic Receptors by ?-TIA. J. Biol. Chem.. 279(34):35326-35333.
Ford APDW, Daniels DV, Chang DJ, Gever JR, Jasper JR, Lesnick JD, Clarke DE. 1997. Pharmacological pleiotropism of the human recombinant?1A-adrenoceptor: implications for?1-adrenoceptor classification. 121(6):1127-1135.
Hieble J. 2000. Drugs targeting adrenergic receptors: does interaction with a specific subtype confer therapeutic advantage?. Curr Opin Drug Disc Dev. 3(4):370-382.
Hieble JP, Bondinell W, Ruffolo RR. 1995. .alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. Part 1. Molecular Biology and Adrenoceptor Subclassification. J. Med. Chem.. 38(18):3415-3444.
Shannon Kava M, Blue DR, Vimont RL, Clarke DE, Ford APDW. 1998. ?1L-Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. 123(7):1359-1366.
Kojima Y, Sasaki S, Hayashi Y, Tsujimoto G, Kohri K. 2009. Subtypes of ?1-adrenoceptors in BPH: future prospects for personalized medicine. Nat Rev Urol. 6(1):44-53.
Kojima Y, Kubota Y, Sasaki S, Hayashi Y, Kohri K. 2009. Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors. CAS. 2(3):223-239.
Minneman P. 1988. Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+ Pharmacol. Rev. 4087-119.
O'Malley SS, Chen TB, Francis BE, Gibson RE, Burns H, DiSalvo J, Bayne ML, Wetzel JM, Nagarathnam D, Marzabadi M, et al. 1998. Characterization of specific binding of L-762,459, a selective ?1A-adrenoceptor radioligand to rat and human tissues. European Journal of Pharmacology. 348(2-3):287-295.
Ruffolo RR, Bondinell W, Hieble JP. 1995. .alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications. J. Med. Chem.. 38(19):3681-3716.
Schwinn DA, Price RR. 1999. Molecular Pharmacology of Human α1-Adrenergic Receptors:Unique Features of the α1a-Subtype. 36(Suppl. 1):7-10.
Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, Sunada S, Takeo S, Tsujimoto G. 2002. The ?1D-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J. Clin. Invest.. 109(6):765-775.
Yamada S, Ito Y, Tsukada H. 2011. ?1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics. 72(2):205-217.
Yan M, Sun J, I Bird P, Liu DL, Grigg M, Lim YL. 2001. ?1A- and ?1B-adrenoceptors are the major subtypes in human saphenous vein. Life Sciences. 68(10):1191-1198.
Ziolkowski N, Grover AK. 2010. Functional linkage as a direction for studies in oxidative stress: ?-adrenergic receptorsThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.. Can. J. Physiol. Pharmacol.. 88(3):220-232.